Repositorio Dspace

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study

Mostrar el registro sencillo del ítem

dc.contributor.author Roos, Izanne
dc.contributor.author Sharmin, Sifat
dc.contributor.author Horakova, Dana
dc.contributor.author Kubala-Havrdova, Eva
dc.contributor.author Libertinova, Jana
dc.contributor.author Vachova, Marta
dc.contributor.author Alroughani, Raed
dc.contributor.author Boz, Cavit
dc.contributor.author Rous, Zuzana
dc.contributor.author Buzzard, Katherine
dc.contributor.author Skibina, Olga
dc.contributor.author Peterka, Marek
dc.contributor.author Hradilek, Pavel
dc.contributor.author Mares, Miroslav
dc.contributor.author Coles, Alasdair
dc.contributor.author Brown, J-William-L
dc.contributor.author Eichau-Madueno, Sara
dc.contributor.author Foschi, Matteo
dc.contributor.author Prevost, Julie
dc.contributor.author Terzi, Murat
dc.contributor.author Prat, Alexandre
dc.contributor.author Girard, Marc
dc.contributor.author Meca-Lallana, José-Eustasio
dc.contributor.author John, Nevin
dc.contributor.author Blanco, Yolanda
dc.contributor.author van-der-Walt, Anneke
dc.contributor.author Butzkueven, Helmut
dc.contributor.author Recmanova, Eva
dc.contributor.author Laureys, Guy
dc.contributor.author Ampapa, Radek
dc.contributor.author Macdonell, Richard
dc.contributor.author Pavelek, Zbysek
dc.contributor.author Khoury, Samia-J
dc.contributor.author D'Amico, Emanuele
dc.contributor.author Gerlach, Oliver
dc.contributor.author Van-Pesch, Vincent
dc.contributor.author Maimone, Davide
dc.contributor.author Romero-Ferrando, Beatriz
dc.contributor.author McCombe, Pamela
dc.contributor.author Mrabet, Saloua
dc.contributor.author Willekens, Barbara
dc.contributor.author Cardenas-Robledo, Simón
dc.contributor.author Ramo-Tello, Cristina
dc.contributor.author Stourac, Pavel
dc.contributor.author Houskova, Jana
dc.contributor.author Shaygannejad, Vahid
dc.contributor.author Hodgkinson, Suzanne
dc.contributor.author Cartechini, Elisabetta
dc.contributor.author Kermode, Allan-G
dc.contributor.author Fabis-Pedrini, Marzena
dc.contributor.author Carroll, William-M
dc.contributor.author Slee, Mark
dc.contributor.author Sánchez-Menoyo, José-Luis
dc.contributor.author Al-Asmi, Abdullah
dc.contributor.author Mathey, Guillaume
dc.contributor.author Giannesini, Claire
dc.contributor.author Michel, Laure
dc.contributor.author Ciron, Jonathan
dc.contributor.author de-Seze, Jerome
dc.contributor.author Ruet, Aurelie
dc.contributor.author Kwiatkowski, Arnaud
dc.contributor.author Zephir, Helene
dc.contributor.author Papeix, Caroline
dc.contributor.author Lebrun-Frenay, Christine
dc.contributor.author Moreau, Thibault
dc.contributor.author Berger, Eric
dc.contributor.author Clavelou, Pierre
dc.contributor.author Pelletier, Jean
dc.contributor.author Casez, Olivier
dc.contributor.author Bourre, Bertrand
dc.contributor.author Wahab, Abir
dc.contributor.author Magy, Laurent
dc.contributor.author Camdessanche, Jean-Philippe
dc.contributor.author Doghri, Ines
dc.contributor.author Tchikviladze, Maia
dc.contributor.author Sellebjerg, Finn
dc.contributor.author Romme-Christensen, Jeppe
dc.contributor.author Jensen, Henrik-Boye
dc.contributor.author Illes, Zsolt
dc.contributor.author Bramow, Stephan
dc.contributor.author Rasmussen, Peter
dc.contributor.author Stilund, Morten-Leif
dc.contributor.author Schafer, Jakob
dc.contributor.author Kant, Matthias
dc.contributor.author Weglewski, Arkadiusz
dc.contributor.author Vukusic, Sandra
dc.contributor.author Magyari, Melinda
dc.contributor.author Laplaud, David-Axel
dc.contributor.author Kalincik, Tomas
dc.date.accessioned 2026-09-17T12:13:40Z
dc.date.available 2026-09-17T12:13:40Z
dc.date.issued 2026-05-20
dc.identifier.issn 0022-3050
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28109
dc.description.abstract BACKGROUND: Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). METHODS: Patients with relapse-onset MS treated with ocrelizumab, fingolimod, natalizumab or alemtuzumab for ?6 months were identified from three registries: MSBase, OFSEP and Danish MS Registry. Pairwise comparisons were performed in the overall cohort and 14 predefined clinicodemographic subgroups based on sex, disease activity, MS duration, Expanded Disability Status Scale, prior therapy and reason for prior treatment cessation. Relapses, progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) were compared in pairwise-censored groups. RESULTS: Fingolimod was associated with a higher annualised relapse rate (ARR) (0.14 vs 0.06, p<0.001), relapse risk (HR 2.26, 95% CI 1.98 to 2.58), RAW (1.62, 1.08 to 2.43) and lower risk of disability improvement (0.78, 0.63 to 0.96) than ocrelizumab. Superiority of ocrelizumab over fingolimod on relapses was maintained in all subgroups. Natalizumab was associated with marginally higher ARR (0.10 vs 0.07, p<0.001), relapse risk (1.35, 1.16 to 1.57) and RAW (1.77, 1.07 to 2.94) than ocrelizumab. Alemtuzumab was associated with higher ARR (0.18 vs 0.12, p<0.001) and relapse risk (1.48, 1.25 to 1.76) than ocrelizumab, but there was no evidence for a difference in risk of RAW. There was no evidence for a difference on PIRA in any comparisons. Ocrelizumab was superior to natalizumab and alemtuzumab on relapses in patients who were not treatment-naïve, experienced disease activity on the prior therapy or stopped prior therapy due to lack of efficacy. CONCLUSIONS: Ocrelizumab provides superior control of relapses and RAW, especially among patients with prior on-treatment disease activity. Treatment of PIRA remains an unmet need.
dc.language.iso eng
dc.publisher BMJ PUBLISHING GROUP
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use/administration & dosage
dc.subject.mesh Female
dc.subject.mesh Male
dc.subject.mesh Adult
dc.subject.mesh Registries
dc.subject.mesh Natalizumab/pharmacology
dc.subject.mesh Immunologic Factors/pharmacology
dc.subject.mesh Fingolimod Hydrochloride/pharmacology
dc.subject.mesh Middle Aged
dc.subject.mesh Alemtuzumab/pharmacology
dc.subject.mesh Cohort Studies
dc.subject.mesh Multiple Sclerosis/drug therapy
dc.subject.mesh Immunosuppressive Agents/pharmacology
dc.subject.mesh Denmark
dc.subject.mesh Disease Progression
dc.subject.mesh Treatment Outcome
dc.title Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42161588
dc.relation.publisherversion https://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2026-338424
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1136/jnnp-2026-338424
dc.journal.title JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
dc.identifier.essn 1468-330X


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta